ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

ALX Oncology Holdings Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE – Research Report), ALX On...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

Jefferies analyst initiated coverage with a Buy rating on ALX Oncology Holdings today and set a price target of $4.00. In addition to Jefferies, AL...

ALX Oncology Holdings (ALXO) Gets a Buy from Jefferies

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Veeva Systems (VEEV – Research Report), ALX Oncology Holdings (AL...

Current Quarter	$-0.33	Next Quarter	$-0.34
Current Year	$-1.77	Next Year	$-1.1
QoQ Growth	-3.0%	YoY Growth	+37.9%
3Y EPS CAGR	-7.6%	Target Price	$2.50
Consensus	Buy	Upside	+74.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALXO	$1.43	+5.15%	178.06K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALXO	$1.43	+5.1%	178.06K
3
4
5
6

ALXO

ALXO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get ALX Oncology Holdings Inc. Data in Excel

Get ALX Oncology Holdings Inc. Data in Excel